Neurocrine Biosciences (NBIX) EPS (Basic) Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) EPS (Basic) Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -301.82% |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 1.21% |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | -17.09% |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 13.91% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -2,504.14% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 31.67% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 388.06% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | -99.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.67% |
| Mar 31, 2026 | 2,385.12% |
| Dec 31, 2025 | 50.43% |
| Sep 30, 2025 | 64.16% |
| Jun 30, 2025 | 68.39% |
| Mar 31, 2025 | -81.78% |
| Dec 31, 2024 | -32.07% |
| Sep 30, 2024 | 51.25% |
| Jun 30, 2024 | -34.10% |
| Mar 31, 2024 | 155.13% |
| Dec 31, 2023 | 62.73% |
| Sep 30, 2023 | 18.71% |
| Jun 30, 2023 | 653.51% |
| Mar 31, 2023 | -640.86% |
| Dec 31, 2022 | 1,303.91% |
| Sep 30, 2022 | 200.95% |
| Jun 30, 2022 | -139.53% |
| Mar 31, 2022 | -57.20% |
| Dec 31, 2021 | -102.07% |
| Sep 30, 2021 | 138.49% |